Suddenly, Poison Pills Are Relevant AgainFrank Aquila
Shareholder rights plans, so-called poison pills, have long drawn the ire of the institutional investor community and have lost favor with Corporate America. But a Delaware judge's recent decision to uphold Airgas's poison pill—followed by Air Products & Chemicals's prompt termination of its hostile bid—confirms that rights plans are still the most potent takeover defense available to targets of unsolicited bids.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.
- Bitcoin Futures Deliver Wild Ride as Debut Brings Rally, Halts
- Investors Told to Brace for Steepest Rate Hikes Since 2006
- A Manager of $42 Billion Fears Bubble in World's Biggest Stocks
- World's Second-Tallest Building Opens With a Whimper After Delay
- Longtime NPR Host Tom Ashbrook Is Facing Misconduct Allegations